We are live on
!
Find out more
Ensign Peak Advisors Portfolio holdings
AUM
$53.7B
1-Year Est. Return
29.47%
This Fund
S&P 500
This Quarter
Est. Return
+13.33%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
–
AUM
$54.8B
AUM Growth
+$4.24B
(+8.4%)
Cap. Flow
-$502M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
29.94%
Holding
1,776
New
37
Increased
449
Reduced
1,142
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$158M |
| 2 |
Uber
UBER
|
+$110M |
| 3 |
Blackstone Secured Lending
BXSL
|
+$97.3M |
| 4 |
Amazon
AMZN
|
+$76.3M |
| 5 |
PayPal
PYPL
|
+$75.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$184M |
| 2 |
Crown Castle
CCI
|
+$173M |
| 3 |
CME Group
CME
|
+$125M |
| 4 |
Gilead Sciences
GILD
|
+$119M |
| 5 |
Amgen
AMGN
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.81% |
| 2 | Healthcare | 15.16% |
| 3 | Financials | 13.11% |
| 4 | Consumer Discretionary | 9.82% |
| 5 | Communication Services | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
ANI Pharmaceuticals
ANIP
$1.84B
| $845K | ﹤0.01% |
12,217
-616
| -5% | -$37.2K |
|
1427
Rogers Corp
ROG
$2.13B
| $842K | ﹤0.01% |
7,092
-358
| -5% | -$41.9K |
|
|
EFC
1428
Ellington Financial
EFC
$1.7B
| $841K | ﹤0.01% |
71,208
-3,592
| -5% | -$43.2K |
|
|
ROIC
1429
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $838K | ﹤0.01% |
65,384
-3,298
| -5% | -$43.9K |
|
1430
MP Materials
MP
$7.35B
| $837K | ﹤0.01% |
58,508
-2,952
| -5% | -$46.7K |
|
1431
Cracker Barrel
CBRL
$1.2B
| $836K | ﹤0.01% |
11,501
-580
| -5% | -$42K |
|
1432
Scansource
SCSC
$1.16B
| $834K | ﹤0.01% |
18,946
-956
| -5% | -$39K |
|
|
DEA
1433
Easterly Government Properties
DEA
$1.17B
| $833K | ﹤0.01% |
28,955
-1,461
| -5% | -$44.4K |
|
1434
Quanex
NX
$893M
| $831K | ﹤0.01% |
21,623
-1,091
| -5% | -$36.4K |
|
1435
Donnelley Financial Solutions
DFIN
$1.31B
| $825K | ﹤0.01% |
13,303
-671
| -5% | -$42K |
|
1436
Privia Health
PRVA
$3.13B
| $820K | ﹤0.01% |
41,877
-2,113
| -5% | -$44.6K |
|
|
NARI
1437
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $820K | ﹤0.01% |
17,097
-863
| -5% | -$46.1K |
|
1438
Vor Biopharma
VOR
$1.08B
| $820K | ﹤0.01% |
17,304
| – | – |
|
1439
AMN Healthcare
AMN
$1.35B
| $820K | ﹤0.01% |
13,115
-6,472
| -33% | -$440K |
|
1440
Federated Hermes
FHI
$4.59B
| $819K | ﹤0.01% |
22,686
-1,144
| -5% | -$40.2K |
|
1441
Interface
TILE
$2B
| $819K | ﹤0.01% |
48,716
-2,458
| -5% | -$34K |
|
1442
Guardant Health
GH
$19B
| $818K | ﹤0.01% |
39,650
-2,000
| -5% | -$42.9K |
|
1443
NBT Bancorp
NBTB
$2.79B
| $816K | ﹤0.01% |
22,257
-1,123
| -5% | -$40.6K |
|
1444
Columbia Sportswear
COLM
$3.3B
| $815K | ﹤0.01% |
10,043
-507
| -5% | -$40.3K |
|
1445
Tencent Music
TME
$15.6B
| $815K | ﹤0.01% |
72,800
| – | – |
|
1446
NeoGenomics
NEO
$1.74B
| $813K | ﹤0.01% |
51,740
-2,610
| -5% | -$40.3K |
|
|
PINC
1447
DELISTED
Premier
PINC
| $813K | ﹤0.01% |
36,784
-1,856
| -5% | -$40.2K |
|
|
PRFT
1448
DELISTED
Perficient Inc
PRFT
| $811K | ﹤0.01% |
14,399
-726
| -5% | -$47.5K |
|
1449
Vestis
VSTS
$2.03B
| $810K | ﹤0.01% |
42,034
-2,121
| -5% | -$42K |
|
1450
CNX Resources
CNX
$4.84B
| $810K | ﹤0.01% |
34,128
-1,722
| -5% | -$35.7K |
|
Similar funds
SCP
Ensign Peak Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Ensign Peak Advisors held 1,776 positions worth $54.8B, up 8.4% from $50.5B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 5%. Ensign Peak Advisors opened 37 new positions and exited 51, leaving the 1,776-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
- Ensign Peak Advisors's largest Q1 2024 buy was Blackstone Secured Lending: 3,319,725 shares worth $103M.
- Ensign Peak Advisors added most to Eli Lilly in Q1 2024, an estimated $158M increase.
- Ensign Peak Advisors's biggest Q1 2024 reduction was Vertex Pharmaceuticals, cutting an estimated $184M.
- Ensign Peak Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q1 2024, selling an estimated $66.5M.
- Ensign Peak Advisors's ten largest holdings make up 30% of its $54.8B portfolio in Q1 2024.
- Ensign Peak Advisors opened 37 new positions and closed 51 in Q1 2024.
- Ensign Peak Advisors's portfolio value rose 8.4% quarter-over-quarter to $54.8B.
Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.